Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy (Q36600828)

15 August 2017

1 reference

title

Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy (English)

1 reference

15 August 2017

0 references

G Mark Baillie

1 reference

15 August 2017

publication date

1 October 2006

1 reference

American Journal of Health-System Pharmacy

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

issue

19 Suppl 5

1 reference

15 August 2017

page(s)

S10-6

1 reference

Infections in solid-organ transplant recipients

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Infection in organ-transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Severing the Gordian knot of prevention of cytomegalovirus in liver transplant recipients: the principle is the sword

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060378

31 March 2020

Identifiers

DOI

10.2146/AJHP060378

1 reference

15 August 2017

1 reference